Talzenna OverviewTalazoparib (trade name Talzenna, BMN-673) is an orally available poly ADP ribose polymerase (PARP) inhibitor currently in development by Pfizer for the treatment of advanced breast cancer patients with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. The U.S. FDA approved Talzenna (talazoparib) for patients with a germline BRCA-mutated, HER2-negative locally advanced or metastatic breast c...
Read more Talzenna Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Talazoparib
Recent Talzenna Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 0.25mg, 1mg
NDC Database Records for Talzenna: (3 results)Sorted by National Drug Code
- 0069-0296 Talzenna .25 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
- 0069-1195 Talzenna 1 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
- 63539-295 Talzenna 1 mg Oral Capsule by U.S. Pharmaceuticals